Skip to main content

Call for papers - Advances in the treatment of systemic lupus erythematosus

Guest Editors

Ioannis Parodis, MD, PhD, Karolinska Institutet, Sweden
Chang-Hee Suh, MD, PhD, Ajou Univ. School of Medicine, South Korea
Fangfang Sun, MD, Renji Hospital, Shanghai Jiaotong University, China
Jiuliang Zhao, MD, Peking Union Medical College Hospital, China

Submission Status: Open   |   Submission Deadline: 20 December 2024 

BMC Rheumatology is calling for submissions to our Collection on Advances in the treatment of systemic lupus erythematosus. 

This Collection aims to further the understanding of systemic lupus erythematosus treatments and spotlight innovative and tailored therapeutic interventions for the future. Systemic lupus erythematosus (SLE) is a multifaceted autoimmune condition, that necessitates diverse treatment approaches ranging from NSAIDs to immunosuppressive medications, yet there remains a pressing need for advancements that target its underlying mechanisms and enhance patient outcomes. Innovations in SLE therapies hold promise for mitigating symptoms, reducing side effects, and improving overall quality of life. However, the intricate nature of the disease poses challenges in developing personalized treatments, underscoring the importance of continued research and exploration in rheumatology to deliver tailored interventions for individuals grappling with SLE.

New Content ItemThis Collection supports and amplifies research related to SDG 3:  Good Health and Well-Being.

Meet the Guest Editors

Back to top

Ioannis Parodis, MD, PhD, Karolinska Institutet, Sweden

Dr Ioannis Parodis studied Medicine at the National and Kapodistrian University of Athens, Greece, and graduated in 2006. He has an interest in B cell biology and novel treatments for systemic lupus erythematosus and lupus nephritis. Currently, Dr Parodis holds a permanent position as a senior consultant Rheumatologist at the Karolinska University Hospital in Stockholm, Sweden, and educational leadership positions at the medical program of Karolinska Institutet. His research has focused on identifying biomarkers and calibrating predictive models for diagnostics, clinical and immune responses to therapies, and long-term prognosis in systemic lupus erythematosus and lupus nephritis. Since 2021, Dr Parodis is also affiliated with the Örebro University, Örebro, Sweden.

Chang-Hee Suh, MD, PhD, Ajou University School of Medicine, South Korea

Dr Chang-Hee Suh is a professor and director of Rheumatology at Ajou University School of Medicine serving in these capacities since March 2011. He is also a professor in the Department of Molecular Science and Technology at Ajou University serving in this role since February 2020. He obtained his MD and PhD in Rheumatology from Yonsei University, Seoul, South Korea. Dr Suh worked as a postdoctoral fellow in the Department of Rheumatology at the University of Pennsylvania. He has published more than 330 peer-reviewed articles with more than 7,000 citations. His research interest is the biomarkers in lupus and the development of new disease-specific treatments in autoimmune diseases.

Fangfang Sun, MD, Renji Hospital, Shanghai Jiaotong University, China

Dr Sun is an associate professor of Rheumatology at Renji Hospital, Shanghai Jiaotong University in China. She completed her MD studies at Peking Union Medical College and conducted her postdoctoral research in the Center of Rheumatology, University Zurich Hospital.  Her research includes risk factors, comorbidities, personalized disease management, and flare prevention of SLE with cohort studies and randomized controlled trials. She works as a youth member of the Rheumatology Division of Shanghai Medical Association.

Jiuliang Zhao, MD, Peking Union Medical College Hospital, China

Dr Jiuliang Zhao is a professor of Rheumatology and deputy director of the Department of Rheumatology and Clinical Immunology at Peking Union Medical College Hospital (PUMCH), which has long been considered the top one hospital in China. Dr Zhao’s major research interests are pathogenesis and clinical studies for systemic lupus erythematosus and antiphospholipid syndrome. His team has established a prospective multicenter cohort Chinese SLE Treatment and Research group (CSTAR) comprising over 5,000 lupus patients. Dr Zhao has authored 53 articles as either the first/co-first author or the corresponding author in journals such as Autoimmunity Reviews, Pharmacology & Therapeutics, Rheumatology (Oxford), RMD Open, and Lupus. Dr Zhao serves as a vice president of the Chinese Rheumatology Association (CRA) Young Committee, and vice president of the Asia Pacific League of Associations for Rheumatology (APLAR) Young Rheumatologist Committee.

About the Collection

BMC Rheumatology is calling for submissions to our Collection on Advances in the treatment of systemic lupus erythematosus.  

Systemic lupus erythematosus (SLE) is a complex autoimmune disease that affects various organs and systems in the body. Characterized by inflammation, SLE can lead to symptoms ranging from joint pain and skin rashes to more severe manifestations involving the kidneys, heart, and lungs. Currently, treatment options for SLE include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and immunosuppressive medications. While these treatments can help manage symptoms, there is an ongoing need for advancements that address the underlying mechanisms of the disease and improve overall outcomes for patients.

Innovation in therapies for SLE has the potential to enhance treatment efficacy, reduce side effects, and ultimately improve the quality of life for individuals affected by the disease. Despite progress, challenges persist in developing targeted and personalized treatments for SLE, as the heterogeneity of the disease presents obstacles in understanding and addressing its diverse manifestations. Exploring these emerging therapies and understanding the challenges associated with them is crucial for advancing the field of rheumatology and providing innovative solutions for individuals living with SLE. We encourage submissions covering a wide array of topics, including but not limited to:

  • Novel therapeutic approaches targeting specific pathways in SLE
  • Personalized medicine strategies for SLE treatment
  • Immunomodulatory interventions and their impact on disease progression
  • Biomarkers for predicting and monitoring treatment responses in SLE
  • Challenges in clinical trial design and implementation for SLE therapies
  • Advances in the design and implementation of clinical trials for SLE therapies
  • Patient perspectives on the impact of emerging treatments for SLE
  • Digital health solutions and telemedicine solutions for treating or managing SLE

Image credit: tashatuvango /

There are currently no articles in this collection.

Submission Guidelines

Back to top

This Collection welcomes submission of original Research Articles. Should you wish to submit a different article type, please read our submission guidelines to confirm that type is accepted by the journal. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a Collection, please select " Advances in the treatment of systemic lupus erythematosus" from the dropdown menu.

Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.

The Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.